Skip to content

Fetuin-A, a Promising Serum Biomarker for Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD)

Role of Fetuin-A, as a non-invasive Biomarker in Diagnosis and Assessment of severity of Non-Alcoholic Fatty Liver Disease (NAFLD)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202309644280965
Enrollment
100
Registered
2023-09-21
Start date
2022-12-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

NAFLD group

Sponsors

Benha University Hospitals
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.a dull or aching pain in the top right of the tummy (over the lower right side of the ribs) 2. extreme tiredness 3.unexplained weight loss 4.weakness

Exclusion criteria

Exclusion criteria: 1.Patients below the age of 18. 2.patients with a history of significant alcohol intake exceeding 40 g/d in males and 20 g/d in females over the past 5 years. 3.presence of concomitant hepatitis B and hepatitis C virus infection. 4.patients with symptoms and signs suggesting (hemochromatosis, Wilson’s disease, alpha-one anti-trypsin deficiency and autoimmune hepatitis). 5.patients with hepatobiliary malignancy and pregnant females (unfit for Fibroscan & CAP). 6.Patients who use these medications; steatogenic drugs (amiodarone, valproic acid, antiretroviral drugs, methotrexate, and tetracyclines), or medicines that are used for the management of NAFLD (Vitamin E, metformin, and thiazolidinediones) .

Design outcomes

Primary

MeasureTime frame
diagnosis of NAFLD based on abdominal U/S and Fibroscan with CAP with or without elevated liver enzymes

Secondary

MeasureTime frame
diagnosis of NAFLD with Fetuin-A biomarker assessment

Countries

Egypt

Contacts

Public ContactMohamed Elhoseeny

Lecturer

mohamedM.elhoseeny@gmail.com00201002719185

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026